Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00387959
Other study ID # 06-066
Secondary ID MSKCC-06066
Status Completed
Phase Phase 2
First received October 12, 2006
Last updated December 22, 2015
Start date July 2006
Est. completion date April 2014

Study information

Verified date December 2015
Source Memorial Sloan Kettering Cancer Center
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

RATIONALE: Giving low doses of chemotherapy, such as cyclophosphamide and fludarabine, total-body irradiation, and rituximab before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving cyclosporine and mycophenolate mofetil after the transplant may stop this from happening.

PURPOSE: This phase II trial is studying how well giving chemotherapy and radiation therapy together with rituximab and an umbilical cord blood transplant works in treating patients with B-cell non-Hodgkin's lymphoma.


Description:

OBJECTIVES:

Primary

- Determine the overall and event-free survival at 1 year in patients with B-cell lymphoid malignancies treated with a nonmyeloablative conditioning regimen, rituximab, and umbilical cord blood (UCB) transplantation (UCBT).

Secondary

- Determine the speed of neutrophil and platelet recovery post allograft in these patients.

- Determine the incidence and speed of donor-derived engraftment and contribution of each UCB unit to engraftment in these patients.

- Determine the incidence and severity of acute graft-vs-host disease (GVHD) at 100 days in these patients.

- Determine the incidence and severity of chronic GVHD at 1 year in these patients.

- Determine the incidence of serious infectious complications and correlate with laboratory measurements of immune recovery in these patients.

- Determine the response to vaccination after UCBT in these patients.

- Determine the incidence of treatment-related mortality at 100 days and 180 days in these patients.

- Determine the incidence of malignant relapse or disease progression at 1 and 2 years in these patients.

- Determine the probabilities of overall and event-free survival at 2 years after UCBT in these patients.

- Determine the performance of laboratory studies investigating double-unit biology and correlate with unit engraftment in these patients.

OUTLINE:

- Pre-transplant rituximab therapy: Patients receive rituximab IV on days -8 or -7 and on day -4.

- Nonmyeloablative conditioning regimen: Patients receive fludarabine phosphate IV over 30 minutes on days -6 to -2 and cyclophosphamide IV on day -6. Patients also undergo total-body irradiation on day -1.

- Umbilical cord blood transplantation: Patients undergo umbilical cord blood transplantation on day 0. Patients receive filgrastim (G-CSF) IV or subcutaneously beginning on day 7 and continuing until blood counts recover.

- Post-transplant rituximab therapy: Patients receive rituximab IV on days 7, 14, 21, and 28.

- Graft-vs-host disease prophylaxis: Patients receive cyclosporine IV over 2-4 hours or orally twice daily on days -3 to 100, followed by a taper. Patients also receive mycophenolate mofetil IV or orally three times daily on days -3 to 45, followed by a taper.

Treatment continues in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed periodically for 5 years.

PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.


Recruitment information / eligibility

Status Completed
Enrollment 17
Est. completion date April 2014
Est. primary completion date April 2014
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 70 Years
Eligibility DISEASE CHARACTERISTICS:

- Diagnosis of 1 of the following:

- CD20+* aggressive B-cell non-Hodgkin's lymphoma (NHL), including 1 of the following:

- Diffuse large cell (DLC) NHL meeting 1 of the following criteria:

- Relapsed disease after initial therapy but failed to mobilize or had bone marrow involvement and therefore is not suitable for an autologous stem cell transplantation

- High-intermediate or high-risk, second-line, age-adjusted International Prognostic Index (IPI) score and in second complete remission (CR) or partial remission (PR) after prior autologous stem cell transplantation

- Failed prior autologous stem cell transplantation and in at least PR after salvage chemotherapy

- Large cell transformation of indolent NHL/chronic lymphocytic leukemia (CLL) meeting the following criteria:

- CR/PR of the large cell component of disease after salvage chemotherapy or autologous stem cell transplantation

- Mantle cell lymphoma meeting 1 of the following criteria:

- High-risk, as defined by p53 positivity and in first CR/PR after initial therapy

- Relapsed disease after initial therapy and in second or third CR/PR after salvage chemotherapy

- CD20+* indolent NHL or CLL meeting the following criteria:

- Must be in second or subsequent progression (pre-allograft cytoreduction necessary but CR/PR not required)

- Indolent NHL includes, but is not limited to, any of the following:

- Follicular NHL

- Small cell NHL

- Marginal zone NHL NOTE: *CD20 positivity must be demonstrated within the past 12 months

- Relapsed disease must be biopsy proven

- Prior pre-allograft cytoreduction may have included 1 of the following:

- Single autologous stem cell transplantation with high-dose chemotherapy conditioning, if appropriate, and no conditioning prior to transplantation

- Two or more courses of intensive combination chemotherapy (e.g., rituximab, irinotecan hydrochloride, cetuximab, epirubicin hydrochloride [RICE]) as appropriate according to diagnosis and prior therapy

- Heavily pre-treated CLL patients in whom further combination chemotherapy is not appropriate may receive single-agent intermediate-dose cyclophosphamide for 2-3 courses

- No mantle cell or DLC NHL with progressive disease at allograft work-up

- No suitable matched related or unrelated donor available

- Two umbilical cord blood (UCB) units available meeting the following criteria:

- Units and recipient must be = 4/6 HLA-A and -B antigen and DRB1 allele matched

- Each unit must have = 1.5 x 10^7 total nucleated cells/recipient body weight

PATIENT CHARACTERISTICS:

- Karnofsky performance score 70-100%

- Creatinine clearance = 50 mL/min

- Bilirubin < 2.5 mg/dL

- AST and ALT = 3 times upper limit of normal (unless due to benign congenital hyperbilirubinemia)

- Spirometry and corrected DLCO = 50% normal

- LVEF = 40%

- Albumin = 2.5 g/dL

- No active and uncontrolled infection at time of transplantation, including active infection with Aspergillus or other mold

- No HIV positivity

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

- No more than 120 days since prior autologous stem cell transplantation

- No more than 60 days since prior chemotherapy

- No prior allogeneic transplantation

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Biological:
filgrastim

rituximab

Drug:
cyclophosphamide

cyclosporine

fludarabine phosphate

mycophenolate mofetil

Procedure:
allogeneic hematopoietic stem cell transplantation

umbilical cord blood transplantation

Radiation:
total-body irradiation


Locations

Country Name City State
United States Memorial Sloan-Kettering Cancer Center New York New York

Sponsors (2)

Lead Sponsor Collaborator
Memorial Sloan Kettering Cancer Center National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Survival at 1 Year After Transplantation The number of patients survival status 1 year after transplantation 1 Year after transplant No
See also
  Status Clinical Trial Phase
Recruiting NCT05540340 - A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant Phase 1
Completed NCT01947140 - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2
Completed NCT00001512 - Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines Phase 1
Recruiting NCT05618041 - The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies N/A
Completed NCT01410630 - FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma
Active, not recruiting NCT04270266 - Mind-Body Medicine for the Improvement of Quality of Life in Adolescents and Young Adults Coping With Lymphoma N/A
Terminated NCT00801931 - Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders Phase 1/Phase 2
Completed NCT01949883 - A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma Phase 1
Completed NCT01682226 - Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies Phase 2
Completed NCT00003270 - Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer Phase 2
Recruiting NCT05019976 - Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma N/A
Recruiting NCT04904588 - HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide Phase 2
Completed NCT04434937 - Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213) Phase 2
Completed NCT01855750 - A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma Phase 3
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Terminated NCT00775268 - 18F- Fluorothymidine to Evaluate Treatment Response in Lymphoma Phase 1/Phase 2
Active, not recruiting NCT04188678 - Resiliency in Older Adults Undergoing Bone Marrow Transplant N/A
Terminated NCT00014560 - Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Phase 1
Recruiting NCT04977024 - SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer Phase 2
Active, not recruiting NCT03936465 - Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer Phase 1